EUVIMEDEUVIMED entdecken
Open Access

Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

Justin M Ko, Tiffany T Mayo, Wilma F Bergfeld, Yves Dutronc, Guanglei Yu, Susan G Ball, Najwa Somani, Brittany G Craiglow

JAMA Dermatology · 01.09.2023 · 159 (9) · 970

DOI: 10.1001/jamadermatol.2023.2581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2023. Verfasst von Justin M Ko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Baricitinib is an oral selective Janus kinase 1/2 inhibitor that has achieved clinically meaningful outcomes for scalp, eyebrow, and eyelash hair regrowth in patients with severe alopecia areata (AA) at week 36 of treatment. Treatment with baricitinib, 4 mg, has resulted in higher response rates than baricitinib, 2 mg, at weeks 36 and 52.

Objective

To determine the efficacy of uptitration to baricitinib, 4 mg, for 24 weeks in patients who had previously not responded to baricitinib, 2 mg (Severity of Alopecia Tool [SALT] score of >20). Design, Setting, and Participants BRAVE-AA1 and BRAVE-AA2 are multicenter, placebo-controlled, phase 3 randomized clinical trials that were initiated on September 24, 2018, and July 8, 2019, respectively, with follow-up to 200 weeks (data cutoffs of November 11, 2021, and November 5, 2021, respectively). This pooled analysis reports long-term extension data up to week 76. At baseline, 1200 adult patients with severe AA (SALT score ≥50) were randomly assigned in a 3:2:2 ratio to receive baricitinib, 4 mg; baricitinib, 2 mg; or placebo. Patients treated with baricitinib remained on the same treatment dose until week 52. Patients were considered nonresponders to baricitinib, 2 mg, if they had a SALT score greater than 20 after 52 weeks of therapy. Main Outcomes and Measures The proportions of patients achieving a SALT score of 20 or lower and clinician-reported outcome for eyebrow hair loss and eyelash hair loss scores of 0 or 1 (full coverage or minimal gaps) with 2-point or higher improvements from baseline (among those with baseline scores ≥2 [significant gaps to no notable hair]) were analyzed through week 76.

Results

At week 52, of the 340 patients (mean [SD] age, 38.4 [12.9] years; 212 [62.4%] female) treated with baricitinib, 2 mg, 212 (62.4%) had a SALT score higher than 20 and were uptitrated to baricitinib, 4 mg. Two-thirds of these patients (142 of 212 [67.0%]) had a baseline SALT score of 95 to 100, indicating very severe AA. At week 76, 55 of the 212 patients (25.9%) had achieved a SALT score of 20 or lower. During the same period, response rates for clinician-reported outcome scores of 0 or 1 increased from 19.3% (31 of 161 patients) to 37.9% (61 of 161 patients) for eyebrows and from 24.1% (33 of 137 patients) to 40.9% (56 of 137 patients) for eyelashes. Conclusions and Relevance In this pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials, uptitration of baricitinib, 2 mg, to baricitinib, 4 mg, in those who did not respond to the 2-mg dose resulted in meaningful improvement of response rates over the subsequent 24 weeks for scalp, eyebrow, and eyelash hair loss. Trial Registration ClinicalTrials.gov Identifiers: NCT03570749 and NCT03899259

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsAdultHumansFemaleMaleHairPyrazolesTreatment OutcomeRandomized Controlled Trials as TopicMulticenter Studies as TopicAzetidinesPurinesSulfonamides

Substanzen

PyrazolesJanus Kinase InhibitorsbaricitinibAzetidinesPurinesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Stanford University School of Medicine, Stanford, California.
  • Department of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham.
  • Departments of Dermatology and Histopathology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Eli Lilly and Company, Indianapolis, Indiana.
  • Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

Zitieren

APA

Ko, J. M., Mayo, T. T., Bergfeld, W. F., Dutronc, Y., Yu, G., Ball, S. G., Somani, N., & Craiglow, B. G. (2023). Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology, 159(9), 970. https://doi.org/10.1001/jamadermatol.2023.2581

Vancouver

Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, et al. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology. 2023;159(9):970. doi:10.1001/jamadermatol.2023.2581

BibTeX
@article{Ko2023,
  author = {Ko, Justin M and Mayo, Tiffany T and Bergfeld, Wilma F and Dutronc, Yves and Yu, Guanglei and Ball, Susan G and Somani, Najwa and Craiglow, Brittany G},
  title = {Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata},
  journal = {JAMA Dermatology},
  year = {2023},
  volume = {159},
  number = {9},
  pages = {970},
  doi = {10.1001/jamadermatol.2023.2581}
}
Kostenlos starten →